Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | US

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
ORGANIGRAM GLOBAL INC. Licensed producer of indoor-grown cannabis and derived products for medical & recreational consumers.	United States of America	OGI
Organon & Co. A global healthcare company focused on women's health, biosimilars, and established brands worldwide.	United States of America	OGN
Oric Pharmaceuticals, Inc. Developing therapies to overcome resistance in lung and prostate cancer.	United States of America	ORIC
Orion Oyj Develops and manufactures human/vet pharma, APIs, and generics for global markets.	Finland	ORNAV
Oruka Therapeutics, Inc. Develops long-acting antibody therapies for chronic inflammatory and skin diseases.	United States of America	ORKA
Orum Therapeutics, Inc. Developing degrader-antibody conjugates for cell-selective protein degradation to treat cancer.	South Korea	475830
OSR Holdings, Inc. Acquires biopharma R&D platforms to build a diverse portfolio of healthcare therapies.	United States of America	OSRH
OS Therapies Inc Developing a cancer vaccine to treat HER2-expressing tumors, primarily Osteosarcoma.	United States of America	OSTX
Otsuka Holdings Co., Ltd. Global healthcare group creating pharmaceuticals and nutraceuticals for worldwide well-being.	Japan	4578
Outlook Therapeutics, Inc. Developing an ophthalmic bevacizumab to treat retinal diseases like wet AMD.	United States of America	OTLK